Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Autoimmune Diseases of the Nervous System Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Autoimmune Diseases of the Nervous System. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Autoimmune Diseases of the Nervous System clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Early Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Early Phase 1: 1, Phase 1: 1.

Research is led by Tongji Hospital (2), Assiut University (1), Arcellx, Inc. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Drug treatment of myasthenia gravis and treatment of crisis (combination_product, 1 trial), followed by CT103A cells, Cyclophosphamide and fludarabine.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Autoimmune Diseases of the Nervous System trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05214612

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG....

Sponsor: Assiut UniversityEnrolling: 301 location
RECRUITINGEarly Phase 1NCT04561557

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous...

Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and...

Sponsor: Tongji HospitalEnrolling: 361 location
RECRUITINGPhase 1NCT06626919

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related...

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG)....

Sponsor: Arcellx, Inc.Enrolling: 3013 locations
RECRUITINGNCT06502015

Biomarkers in Autoimmune Disease of Nervous System

Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and...

Sponsor: Tongji HospitalEnrolling: 500001 location

Frequently Asked Questions

There are currently 4 clinical trials for Autoimmune Diseases of the Nervous System, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Autoimmune Diseases of the Nervous System, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Autoimmune Diseases of the Nervous System, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.